文献速递细菌感染、耐药与抗菌药物医院感染防控

实施EUCAST快速抗菌药物敏感性试验(RAST)检测产碳青霉烯酶/ESBL的大肠埃希菌和肺炎克雷伯菌分离株及其对死亡率的影响

Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

本研究在无先进鉴定系统的条件下,用简单诊断试验预判鉴定后实施EUCAST快速药敏试验(p-RAST),检测含产碳青霉烯酶/ESBL大肠埃希菌和肺炎克雷伯菌的临床血培养,并比较p-RAST组与非RAST组的死亡率。p-RAST组死亡率低于非RAST组(28.6% vs 51.7%,P=0.005)。

要点

  • p-RAST在4、6、8小时的总错误率分别为2.9%、3.9%、3.8%。
  • p-RAST组未接受适当抗生素者(29/45,59.1%)最迟8小时内转为适当治疗。
  • 非RAST组接受不适当抗生素者(79/145,54.5%)至少24小时后才可更改治疗。

核心结论

  • p-RAST可在抗菌药物耐药率高的医院实验室安全使用,并通过缩短转为适当治疗的时间降低死亡率。

研究设计与样本

  • 研究对含产碳青霉烯酶/ESBL大肠埃希菌和肺炎克雷伯菌的临床血培养,在不使用先进鉴定系统(如MALDI-TOF)的情况下,通过简单诊断试验预判鉴定后实施EUCAST RAST(p-RAST),并分析该方法对死亡率的影响。
  • 比较接受p-RAST的血培养患者(p-RAST组,n=49)与未接受p-RAST的患者(非RAST组,n=145)的临床数据。

主要发现

  • p-RAST结果基于539个抗生素-细菌组合分析,4、6、8小时孵育的总错误率分别为2.9%、3.9%、3.8%。
  • p-RAST组未接受适当抗生素的患者(29/45,59.1%)最迟8小时内转为适当治疗。
  • 非RAST组接受不适当抗生素的患者(79/145,54.5%)至少24小时后才可更改治疗。
  • p-RAST组死亡率低于非RAST组(28.6% vs 51.7%,P=0.005)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: With the rise in antimicrobial resistance, there is a growing demand for rapid antimicrobial susceptibility testing (RAST). In this study, we applied the EUCAST RAST method to ESBL/carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolates without using advanced identification systems and analysed the effect of this method on mortality rates Also the clinical impact of this method on patients infected with these bacteria and its effect on mortality rates were investigated. METHODS: RAST was used for clinical blood cultures containing carbapenemase/ESBL-producing E. coli and K. pneumoniae without advanced identification systems (e.g. MALDI TOF), with preliminary identification by simple diagnostic tests (predicted RAST, or p-RAST), and its categorical agreement was investigated. The impact of the method on mortality was analysed by comparing the clinical data of patients whose blood cultures were subject to p-RAST (p-RAST group, n = 49) and those who were not subject to p-RAST (non-RAST group, n = 145). RESULTS: p-RAST results were analysed based on 539 antibiotic-bacteria combinations. Total error rates at 4, 6 and 8 h of incubation were 2.9%, 3.9% and 3.8%, respectively. In the p-RAST group, patients who did not receive appropriate antibiotics (29/45, 59.1%) were switched to appropriate treatment within 8 h at the latest. In contrast, in the non-RAST group, treatment of patients who received inappropriate antibiotics (79/145, 54.5%) could be changed after at least 24 h. Mortality rates were lower in the p-RAST group than in the non-RAST group (28.6% versus 51.7%, P = 0.005). CONCLUSIONS: p-RAST can be used safely in hospital laboratories with high rates of antimicrobial resistance and can reduce mortality rates by shortening the transition time to appropriate treatment.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tayşi MR, Öcal D, Çiçek Şentürk G, et al. Implementation of the EUCAST rapid antimicrobial susceptibility test (RAST) for carbapenemase/ESBL-producing Escherichia coli and Klebsiella pneumoniae isolates, and its effect on mortality. J Antimicrob Chemother. 2024. PMID: 38725249. doi:10.1093/jac/dkae125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。